A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 548 (final count)
- Started
- Dec 21, 2020
- Main results expected
- Nov 13, 2026
- Fully finished
- Mar 5, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period
Measured over: Up to 6 weeks
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Approximately 90 days from last dose; up to 5 years
Incidence and severity of Adverse Events of Special Interest (AESIs)
Measured over: Approximately 90 days from last dose; up to 5 years
Incidence and severity of Serious Adverse Events (SAEs)
Measured over: Approximately 90 days from last dose; up to 5 years
Incidence and severity of grade ≥3 laboratory abnormalities
Measured over: Approximately 90 days from last dose; up to 5 years
Objective Response Rate (ORR)
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04626635 · record last updated 2026-07-02 · checked 2026-11-09 15:47 UTC